CranioSense awarded $5.5M in federal grants to validate non-invasive neurotech monitoring platform
Summary
Philadelphia-based CranioSense received $5.5 million in federal grants to validate their non-invasive brain monitoring platform targeting traumatic brain injury management and ICU neurological monitoring. Federal grant funding from NIH and DoD programs validates the scientific premise and de-risks the technology for subsequent commercial investors. CranioSense's approach aims to replace invasive intracranial pressure monitoring probes with a non-contact external sensing platform.
Why it matters
Federal grant validation for non-invasive ICP monitoring confirms that CranioSense's scientific approach is sound — NIH and DoD reviewers are sophisticated evaluators of neuromonitoring technology. The $5.5M puts them alongside CoMind in the race to commercialize non-invasive intracranial pressure monitoring, potentially the highest-value application in neurocritical care.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial